DNAJ member B6 (DnaJB6) has also been elucidated as a poor prognostic factor for CRC patients, where its overexpression was observed in 39% of the CRC patients, especially in those at the stage of cancer IV compared to the stages I–III. Here, DNAJB6 is linked to colorectal carcinoma.